IPP Bureau
Oceanic-AF study stopped early due to lack of efficacy
By IPP Bureau - November 21, 2023
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Strides receives USFDA approval for Levetiracetam Oral Solution
By IPP Bureau - November 21, 2023
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Health Minister Mandaviya delivers keynote address 2nd Voice of Global South Summit 2023
By IPP Bureau - November 20, 2023
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
AskBio announces first patient randomized in Phase 1 Trial of AB-1005
By IPP Bureau - November 20, 2023
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Lupin receives approval from US FDA for Ganirelix Acetate Injection
By IPP Bureau - November 20, 2023
The product will be manufactured at Lupin’s Nagpur facility in India
Teva announces approval of a generic version of Forteo in US
By IPP Bureau - November 20, 2023
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India
By IPP Bureau - November 17, 2023
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Alkem healthy lungs initiative to promote importance of inhalation therapy
By IPP Bureau - November 17, 2023
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
FDA approves Merck’s Keytruda plus chemotherapy as first line treatment for locally advanced Metastatic HER2-Negative Gastric
By IPP Bureau - November 17, 2023
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Brenntag Specialties and Zeochem expand collaboration for Pharma EMEA
By IPP Bureau - November 17, 2023
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting
By IPP Bureau - November 17, 2023
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
By IPP Bureau - November 16, 2023
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Sanofi completes closing for potential first-in-class vaccine against ExPEC
By IPP Bureau - November 16, 2023
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
By IPP Bureau - November 15, 2023
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
By IPP Bureau - November 15, 2023
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
